Therapeutics for drug-resistant bacteria using arylmyxopyronins
Official title: Therapeutics for drug-resistant bacteria: arylmyxopyronins
Funded at Hackensack University Medical Center · NIH-11372913 · Data updated 2026-11-12
Aimed at new antibiotics, this project tests arylmyxopyronins to treat drug-resistant Acinetobacter and other bacteria, potentially offering options when current drugs fail.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project start | June 20, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $970,361 |
| NIH project number | 5U19AI189168-02 |
| Project ID | NIH-11372913 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with infections caused by drug-resistant Acinetobacter baumannii or related bacteria who may benefit from new oral antibiotic options.
✕Less likely to help
Patients without drug-resistant bacterial infections may not benefit from these specific antibiotics.
What this research studies
This grant explores arylmyxopyronins, a new class of antibiotics that stop bacterial RNA polymerase in a way different from existing drugs. Researchers have already synthesized and tested hundreds of analogs to identify orally available leads with strong activity in the lab and in animal infection models. They are advancing two lead subclasses, APY-GP and APY-GN, with promising in vitro potency and in vivo efficacy, including resistant strains. The work combines lead optimization, preclinical evaluation, and in vivo infection models to move toward safer, effective oral therapies. The study is conducted at Hackensack University Medical Center under a U19 cooperative agreement framework to coordinate multi-project efforts.
Why it matters
Potential benefit: If successful, patients could gain new oral antibiotics effective against drug-resistant infections.
How similar studies have gone: Similar antibiotic development efforts have shown that novel mechanisms can overcome resistance, with some leads advancing to clinical testing.
Where this research is happening
-
Hackensack University Medical Center
Hackensack, United States Active
Researchers
- Principal investigator: Ebright, Richard H. — Hackensack University Medical Center
- Study coordinator: Ebright, Richard H.
Related research
Other NIH-funded projects on the same topics.
-
Orally accessible antiviral leaders to fight COVID-19 and related coronaviruses
A research effort to fast-track safe, easy-to-take oral drugs that can treat COVID-19 and other coronaviruses by repurposing and optimizing existing antiviral compounds.
-
Metropolitan Antiviral Drug Accelerator Virology Core
A core team across top hospitals and universities is testing antiviral compounds against SARS-CoV-2 and related coronaviruses to identify promising drugs for COVID-19.
-
Broad-spectrum SARS-CoV-2 protease inhibitor for antiviral therapy
Researchers are developing a new small-molecule drug that blocks a key SARS-CoV-2 enzyme, with potential to treat COVID-19 across multiple virus variants.
-
Metropolitan AntiViral Drug Accelerator: Animal Models
A large NIH-funded effort uses animal models to test new antiviral compounds against SARS-CoV-2 and related viruses to move promising leads toward early development.
-
Metropolis AntiViral Drug Accelerator: Pharmacology Core
A dedicated program to speed up promising antiviral drugs by testing their behavior in the body and choosing the best candidates for further development.
-
Metropolitan Antiviral Drug Accelerator
A national program at Hackensack University Medical Center to help develop and optimize small-molecule drugs that may block key SARS-CoV-2 proteins, potentially slowing COVID-19 replication.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.